Permira is selling Australia's I-Med Radiology Network, which recently entered the U.S. by acquiring StatRad, to Hong Kong-based multinational conglomerate Jardine Matheson.
The Bedford, Massachusetts-based company has reportedly been approached about a possible acquisition by competitor Curium Pharma, Bloomberg reported May 22.
Last week hospitals owned by three big health systems filed suit against CVS Health. The trio filed separately, but all accuse the corporation of robbing them of funds they’re owed through the federal 340B drug pricing program.
Quorum Health said the move will allow it to save money through tax exemptions and provide its 11 hospitals with access to the 340B Drug Pricing Program. The health system is majority-owned by Goldentree Asset Management.
The change would represent an imperfect but, in many cases, perfectly appropriate way to oversee the technology without crimping its capabilities. So say three thought leaders who are close watchers of medical ethics and technologies.
The intrusion was caused by the compromised credentials of a Hartford HealthCare employee. Data stolen included full names, Medicaid ID numbers and patient treatment details.
The country’s largest independent imaging group—located in Fort Worth and employing about 300 physicians—calculated the figure based on an internal analysis of its billing practices.
Jeffrey and Kim Sayward, of Florida, charge that radiologist Eric J. Sax, MD, working for MaineHealth Hospital in Biddeford at the time, failed to identify a dangerous blood clot three years ago.
Washington-based Providence Health and Services denies the allegations. The lawsuit, filed by the state attorney general, details incidents of noncompliance and retaliation dating back to 2021.
Permira is selling Australia's I-Med Radiology Network, which recently entered the U.S. by acquiring StatRad, to Hong Kong-based multinational conglomerate Jardine Matheson.
The Bedford, Massachusetts-based company has reportedly been approached about a possible acquisition by competitor Curium Pharma, Bloomberg reported May 22.
